Eschewing a straw poll from shareholders because of the risk in triggering a poison pill provision, Pershing Square's Bill Ackman now wants a more definitive vote on removing the bulk of the Allergan (AGN +2.6%) board. A special meeting on the issue could happen as early as August. Pershing Square needs consent from at least 25% of the firm's shares to hold the meeting. Mr. Ackman says he has the votes to move forward.
Related ticker: (VRX +1.8%)